- Home
- USEA vs AFMD Comparison
USEA vs AFMD Comparison
Compare USEA & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- AFMD
- Stock Information
- Founded
- USEA 2004
- AFMD 2000
- Country
- USEA Greece
- AFMD Germany
- Employees
- USEA N/A
- AFMD N/A
- Industry
- USEA Marine Transportation
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- AFMD Health Care
- Exchange
- USEA Nasdaq
- AFMD Nasdaq
- Market Cap
- USEA 16.0M
- AFMD 14.5M
- IPO Year
- USEA N/A
- AFMD 2014
- Fundamental
- Price
- USEA $1.36
- AFMD $0.72
- Analyst Decision
- USEA Strong Buy
- AFMD Strong Buy
- Analyst Count
- USEA 1
- AFMD 5
- Target Price
- USEA $6.00
- AFMD $13.50
- AVG Volume (30 Days)
- USEA 73.1K
- AFMD 83.8K
- Earning Date
- USEA 03-18-2025
- AFMD 04-08-2025
- Dividend Yield
- USEA 16.43%
- AFMD N/A
- EPS Growth
- USEA N/A
- AFMD N/A
- EPS
- USEA N/A
- AFMD N/A
- Revenue
- USEA $45,439,000.00
- AFMD $6,287,085.00
- Revenue This Year
- USEA $7.08
- AFMD N/A
- Revenue Next Year
- USEA N/A
- AFMD $225.65
- P/E Ratio
- USEA N/A
- AFMD N/A
- Revenue Growth
- USEA 25.98
- AFMD N/A
- 52 Week Low
- USEA $1.34
- AFMD $0.72
- 52 Week High
- USEA $2.90
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- USEA 24.76
- AFMD 20.90
- Support Level
- USEA $1.40
- AFMD $0.85
- Resistance Level
- USEA $1.97
- AFMD $0.89
- Average True Range (ATR)
- USEA 0.10
- AFMD 0.05
- MACD
- USEA -0.03
- AFMD -0.01
- Stochastic Oscillator
- USEA 3.91
- AFMD 1.24
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.